NCT02054104 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Cheng YH, Wong EW, Cheng CY
Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 2011 Jul-Sep;1(3):209-220. doi: 10.4161/spmg.1.3.17990. Epub 2011 Jul 1. Review.
Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L, Maio M
The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011 Apr;5(2):164-82. doi: 10.1016/j.molonc.2011.02.001. Epub 2011 Feb 18.
Schrump DS
Targeting epigenetic mediators of gene expression in thoracic malignancies. Biochim Biophys Acta. 2012 Jul;1819(7):836-45. doi: 10.1016/j.bbagrm.2012.03.009. Epub 2012 Apr 9. Review.
Zhang M, Hong JA, Kunst TF, Bond CD, Kenney CM, Warga CL, Yeray J, Lee MJ, Yuno A, Lee S, Miettinen M, Ripley RT, Hoang CD, Gnjatic S, Trepel JB, Schrump DS
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoraci

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Details for clinical trial NCT02054104

Clinical trial NCT02054104 - References